The benefit of intravenous immune globulin in the treatment of delayed radiation myelopathy.
Late onset myelopathy
Radiation induced myelitis
Radiotherapy side effects
Spinal cord toxicity
Steroid resistant myelitis
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
19 Sep 2023
19 Sep 2023
Historique:
received:
24
01
2023
accepted:
21
08
2023
medline:
20
9
2023
pubmed:
20
9
2023
entrez:
19
9
2023
Statut:
aheadofprint
Résumé
Delayed radiation myelopathy (DRM) is a rare yet severe complication of radiotherapy. This condition has a progressive pattern that is often irreversible. Several therapeutic strategies have been introduced to alleviate disease complications, including corticosteroids, hyperbaric oxygen, anticoagulants, and antivascular endothelial growth factor (VEGF) agents. However, despite their beneficial effect, they have not been the definitive treatments for DRM. Here we present the case of a 55-year-old woman with a history of multiple myeloma who developed neurological complications 11 months after radiation therapy. As her radiologic findings demonstrated transverse myelitis, based on the DRM diagnostic criteria, the diagnosis of delayed radiation myelitis was reached. Therefore, methylprednisolone pulse therapy was initiated, resulting in the complete resolution of her neurological symptoms. However, on her follow-up examination, although she did not have new neurological complications, magnetic resonance imaging (MRI) demonstrated a residual enhancement in the thoracic spinal cord area. Hence, due to the possibility of myelitis progression and spinal cord atrophy, intravenous immune globulin (IVIG) was administered, resulting in the resolution of lesion enhancement. Considering this outcome and the immunomodulatory properties of IVIG, it could be regarded as a potential therapeutic option in the case of DRM activity.
Identifiants
pubmed: 37726423
doi: 10.1007/s00066-023-02150-1
pii: 10.1007/s00066-023-02150-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Soussain C, Ricard D, Fike JR, Mazeron J‑J, Psimaras D, Delattre J‑Y (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374(9701):1639–1651. https://doi.org/10.1016/S0140-6736(09)61299-X
doi: 10.1016/S0140-6736(09)61299-X
pubmed: 19897130
Carausu M, Beddok A, Langer A, Girard N, Bidard F‑C, Massiani M‑A et al (2019) Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. J Immunother Cancer 7(1):317. https://doi.org/10.1186/s40425-019-0803-x
doi: 10.1186/s40425-019-0803-x
pubmed: 31753021
pmcid: 6868866
Wong CS, Fehlings MG, Sahgal A (2015) Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord 53(8):574–580. https://doi.org/10.1038/sc.2015.43
doi: 10.1038/sc.2015.43
pubmed: 25800695
Sarica F, Ozgur K, Cekinmez M, Nur A, Kadir T (2012) Delayed radiation myelopathy: differential diagnosis with positron emission tomography/computed tomography examination. Asian J Neurosurg 7(4):206. https://doi.org/10.4103/1793-5482.106656
doi: 10.4103/1793-5482.106656
pubmed: 23559989
pmcid: 3613644
Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J et al (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23(7):1337–1341. https://doi.org/10.1038/leu.2009.26
doi: 10.1038/leu.2009.26
pubmed: 19225538
pmcid: 2711213
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376(9757):1989–1999. https://doi.org/10.1016/S0140-6736(10)62051-X
doi: 10.1016/S0140-6736(10)62051-X
pubmed: 21131037
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C et al (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(1):57–73. https://doi.org/10.1016/S1470-2045(18)30687-9
doi: 10.1016/S1470-2045(18)30687-9
pubmed: 30559051
pmcid: 6318225
Hsu P‑C, Chen S‑J (2017) Longitudinal extensive transverse myelitis with an abnormal uFLC ratio in a pediatric patient. Medicine 96(52):e9389. https://doi.org/10.1097/MD.0000000000009389
doi: 10.1097/MD.0000000000009389
pubmed: 29384915
pmcid: 6392810
van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410–427. https://doi.org/10.1016/S0140-6736(21)00135-5
doi: 10.1016/S0140-6736(21)00135-5
pubmed: 33516340
Al-Salama ZT, Garnock-Jones KP, Scott LJ (2017) Ixazomib: a review in relapsed and/or refractory multiple myeloma. Target Oncol 12(4):535–542. https://doi.org/10.1007/s11523-017-0504-7
doi: 10.1007/s11523-017-0504-7
pubmed: 28660423
Gilden DH, Beinlich BR, Rubinstien EM, Stommel E, Swenson R, Rubinstein D et al (1994) Varicella-zoster virus myelitis: an expanding spectrum. Neurology 44(10):1818–1818. https://doi.org/10.1212/WNL.44.10.1818
doi: 10.1212/WNL.44.10.1818
pubmed: 7936229
Vickrey E, Allen S, Mehta J, Singhal S (2009) Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115(1):229–232. https://doi.org/10.1002/cncr.24006
doi: 10.1002/cncr.24006
pubmed: 19090004
Zhang C, Tian D‑C, Yang C‑S, Han B, Wang J, Yang L et al (2017) Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol 74(8):1010. https://doi.org/10.1001/jamaneurol.2017.1336
doi: 10.1001/jamaneurol.2017.1336
pubmed: 28692708
pmcid: 5822186
Chiganer EH, Hryb JP, Carnero Contentti E (2017) Mielitis y lupus: clínica, diagnóstico y tratamiento. Revisión. Reumatol Clín 13(6):344–348. https://doi.org/10.1016/j.reuma.2016.06.004
doi: 10.1016/j.reuma.2016.06.004
pubmed: 27567298
Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M et al (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52(9):969–972. https://doi.org/10.2169/internalmedicine.52.7885
doi: 10.2169/internalmedicine.52.7885
pubmed: 23648715
Feki A, Sellami I, Gassara Z, Ben Djemaa S, Ezzeddine M, Kallel MH et al (2022) Spinal Paget’s disease with bilevel cord compression and ischemic non-compressive myelopathy treated with zoledronic acid. Clin Case Reports. https://doi.org/10.1002/ccr3.6263
doi: 10.1002/ccr3.6263
Makranz C, Nachmias B, Gatt EM, Eliahou R, Lossos A (2018) Lenalidomide-related spinal cord infarction in primary amyloidosis. Arch Clin Med Case Rep. https://doi.org/10.26502/acmcr.96550034
doi: 10.26502/acmcr.96550034
Schultheiss TE (2008) The radiation dose–response of the human spinal cord. Int J Radiat Oncol 71(5):1455–1459. https://doi.org/10.1016/j.ijrobp.2007.11.075
doi: 10.1016/j.ijrobp.2007.11.075
Gibbs IC, Patil C, Gerszten PC, Adler JR, Burton SA (2009) Delayed Radiation-Induced Myelopathy After Spinal Radiosurgery. Neurosurgery 64(2):A67–72. https://doi.org/10.1227/01.NEU.0000341628.98141.B6
doi: 10.1227/01.NEU.0000341628.98141.B6
pubmed: 19165076
Kubo K, Wadasaki K, Yamane H, Doi M. Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature. Int Cancer Conf J [Internet]. 2019 Jul 13;8(3):118–21. Available from: https://doi.org/10.1007/s13691-019-00367-5
Nozaki S, Naiki T, Hamamoto S, Ando R, Iida K, Kawai N et al (2017) A Case of Delayed Radiation Myelopathy of the Thoracic Vertebrae Following Low Dose Radiation Therapy for Metastatic Renal Cell Carcinoma. Urol Case Reports [Internet. Feb, vol 11. Available from, pp 66–68 https://doi.org/10.1016/j.eucr.2017.01.005
Liu CY, Yim BT, Wozniak AJ. Anticoagulation Therapy for Radiation-Induced Myelopathy. Ann Pharmacother [Internet]. 2001 Feb 26;35(2):188–91. Available from: https://doi.org/10.1345/aph.10168
Calabrò F, Jinkins JR. MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol [Internet]. 2000 Jun 21;10(7):1079–84. Available from: https://doi.org/10.1007/s003309900278
Psimaras D, Tafani C, Ducray F, Leclercq D, Feuvret L, Delattre JY, et al. Bevacizumab in late-onset radiation-induced myelopathy. Neurology [Internet]. 2016 Feb 2;86(5):454–7. Available from: https://doi.org/10.1212/WNL.0000000000002345
Khan M, Ambady P, Kimbrough D, Shoemaker T, Terezakis S, Blakeley J, et al. Radiation-Induced Myelitis: Initial and Follow-Up MRI and Clinical Features in Patients at a Single Tertiary Care Institution during 20 Years. Am J Neuroradiol [Internet]. 2018 May 17; Available from: https://doi.org/10.3174/ajnr.A5671
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG Treatment and Prognosis in Guillain–Barré Syndrome. J Clin Immunol [Internet]. 2010 May 16;30(S1):74–8. Available from: https://doi.org/10.1007/s10875-010-9407-4
Tzekou A, Fehlings MG. Treatment of Spinal Cord Injury with Intravenous Immunoglobulin G: Preliminary Evidence and Future Perspectives. J Clin Immunol [Internet]. 2014 Jul 11;34(S1):132–8. Available from: https://doi.org/10.1007/s10875-014-0021-8
Owen T, Fung AS. Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report. Clin Lung Cancer [Internet]. 2022 Dec;23(8):e563–7. Available from: https://doi.org/10.1016/j.cllc.2022.08.012
Marchioni E, Marinou-Aktipi K, Uggetti C, Bottanelli M, Pichiecchio A, Soragna D, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol [Internet]. 2002 Jan;249(1):100–4. Available from: https://doi.org/10.1007/PL00007836